Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Migalis Aps has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is localized in 1 distinct art unit, reflecting a specific technical focus for the company's current patent applications. The matter is being reviewed by 1 distinct examiner, creating 1 point of contact for the company's interactions with the USPTO. This focused approach suggests that the company is currently concentrating its intellectual property efforts on 1 technical advancement.
MELLER, MICHAEL V is the busiest examiner for the portfolio, currently managing 1 pending office action. Since the portfolio is concentrated in 1 distinct examiner and 1 distinct art unit, the prosecution path is straightforward. Practitioners can focus their efforts on the specific examination style of MELLER, MICHAEL V, as there are no other examiners or art units involved in the current pending matters. This centralized structure allows for a more efficient and targeted prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MELLER, MICHAEL V | 1 | 47.1% | +28.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17911920 | COMPOSITION FOR ENHANCING UROLITHIN PRODUCTION IN A HUMAN SUBJECT | MELLER, MICHAEL V | 9d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17911920 | COMPOSITION FOR ENHANCING UROLITHIN PRODUCTION IN A HUMAN SUBJECT | MELLER, MICHAEL V | 9d |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17911920 | COMPOSITION FOR ENHANCING UROLITHIN PRODUCTION IN A HUMAN SUBJECT | MELLER, MICHAEL V | 1655 | §101§103 | Non-Final OA | 9d | Pending | Sep 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial